XHKG8622
Market cap10mUSD
Dec 23, Last price
0.17HKD
1D
-7.69%
1Q
-25.33%
IPO
-60.47%
Name
Huakang Biomedical Holdings Co Ltd
Chart & Performance
P/E
—
P/S
3.21
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.39%
Rev. gr., 5y
-3.00%
Revenues
25m
-2.77%
Net income
-6m
L+88.03%
CFO
-48k
L
Profile
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxiliary reproductive supplies and equipment; and healthcare products and supplements under the Nutronic brand to customers, as well as through online and offline platforms and channels. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 24,629 -2.77% | 25,330 -3.05% | 26,127 18.94% | ||||||
Cost of revenue | 29,580 | 29,653 | 29,807 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,951) | (4,323) | (3,680) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 68 | 317 | |||||||
Tax Rate | |||||||||
NOPAT | (4,951) | (4,391) | (3,997) | ||||||
Net income | (5,782) 88.03% | (3,075) -27.13% | (4,220) -63.71% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 467 | 2,305 | |||||||
BB yield | -1.05% | -3.08% | |||||||
| Debt | |||||||||
Debt current | 3,959 | 410 | 1,019 | ||||||
Long-term debt | 3,465 | 528 | 2,349 | ||||||
Deferred revenue | 23 | 38 | 53 | ||||||
Other long-term liabilities | 38 | 53 | |||||||
Net debt | (25,511) | (32,365) | (32,839) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (48) | 1,286 | (2,378) | ||||||
CAPEX | (1,502) | (811) | (2,331) | ||||||
Cash from investing activities | (1,153) | (6,109) | (2,055) | ||||||
Cash from financing activities | 1,023 | 2,324 | (1,366) | ||||||
FCF | (7,043) | (3,216) | (4,216) | ||||||
| Balance | |||||||||
Cash | 32,935 | 33,303 | 36,207 | ||||||
Long term investments | |||||||||
Excess cash | 31,704 | 32,036 | 34,901 | ||||||
Stockholders' equity | 755 | 4,578 | 10,457 | ||||||
Invested Capital | 55,423 | 52,491 | 48,819 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 415,962 | 404,639 | 400,000 | ||||||
Price | 0.11 -42.16% | 0.19 -25.40% | 0.25 129.63% | ||||||
Market cap | 44,508 -40.54% | 74,858 -24.54% | 99,200 129.63% | ||||||
EV | 18,997 | 42,493 | 66,361 | ||||||
EBITDA | (1,772) | (1,183) | (731) | ||||||
EV/EBITDA | |||||||||
Interest | 53 | 55 | 102 | ||||||
Interest/NOPBT | |||||||||